Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 246

1.

Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer.

Pantuck AJ, Leppert JT, Zomorodian N, Aronson W, Hong J, Barnard RJ, Seeram N, Liker H, Wang H, Elashoff R, Heber D, Aviram M, Ignarro L, Belldegrun A.

Clin Cancer Res. 2006 Jul 1;12(13):4018-26.

2.

Phase II study of nitric oxide donor for men with increasing prostate-specific antigen level after surgery or radiotherapy for prostate cancer.

Siemens DR, Heaton JP, Adams MA, Kawakami J, Graham CH.

Urology. 2009 Oct;74(4):878-83. doi: 10.1016/j.urology.2009.03.004. Epub 2009 May 24.

PMID:
19476985
3.

Phase-II Study of pomegranate juice for men with prostate cancer and increasing PSA.

Pantuck AJ, Zomorodian N, Belldegrun AS.

Curr Urol Rep. 2006 Jan;7(1):7. No abstract available.

PMID:
16480662
4.

Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy.

Smith MR, Manola J, Kaufman DS, George D, Oh WK, Mueller E, Slovin S, Spiegelman B, Small E, Kantoff PW.

Cancer. 2004 Oct 1;101(7):1569-74.

5.
6.

A randomized, double-blind, placebo-controlled study of the effects of pomegranate extract on rising PSA levels in men following primary therapy for prostate cancer.

Pantuck AJ, Pettaway CA, Dreicer R, Corman J, Katz A, Ho A, Aronson W, Clark W, Simmons G, Heber D.

Prostate Cancer Prostatic Dis. 2015 Sep;18(3):242-8. doi: 10.1038/pcan.2015.32. Epub 2015 Jul 14.

PMID:
26169045
7.

Lycopene and soy isoflavones in the treatment of prostate cancer.

Vaishampayan U, Hussain M, Banerjee M, Seren S, Sarkar FH, Fontana J, Forman JD, Cher ML, Powell I, Pontes JE, Kucuk O.

Nutr Cancer. 2007;59(1):1-7.

PMID:
17927495
8.

Intensive lifestyle changes may affect the progression of prostate cancer.

Ornish D, Weidner G, Fair WR, Marlin R, Pettengill EB, Raisin CJ, Dunn-Emke S, Crutchfield L, Jacobs FN, Barnard RJ, Aronson WJ, McCormac P, McKnight DJ, Fein JD, Dnistrian AM, Weinstein J, Ngo TH, Mendell NR, Carroll PR.

J Urol. 2005 Sep;174(3):1065-9; discussion 1069-70.

PMID:
16094059
9.

Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.

James ND, Caty A, Borre M, Zonnenberg BA, Beuzeboc P, Morris T, Phung D, Dawson NA.

Eur Urol. 2009 May;55(5):1112-23. doi: 10.1016/j.eururo.2008.11.002. Epub 2008 Nov 29.

PMID:
19042080
11.

Effects of a phytotherapeutic agent, PC-SPES, on prostate cancer: a preliminary investigation on human cell lines and patients.

de la Taille A, Hayek OR, Buttyan R, Bagiella E, Burchardt M, Katz AE.

BJU Int. 1999 Nov;84(7):845-50.

PMID:
10532984
12.

Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: an analysis of Radiation Therapy Oncology Group Protocol 92-02.

Valicenti RK, DeSilvio M, Hanks GE, Porter A, Brereton H, Rosenthal SA, Shipley WU, Sandler HM; Radiation Therapy Oncology Group Protocol 92-02.

Int J Radiat Oncol Biol Phys. 2006 Nov 15;66(4):1064-71. Epub 2006 Sep 18.

PMID:
16979837
13.
14.

Induction of apoptosis in low to moderate-grade human prostate carcinoma by red clover-derived dietary isoflavones.

Jarred RA, Keikha M, Dowling C, McPherson SJ, Clare AM, Husband AJ, Pedersen JS, Frydenberg M, Risbridger GP.

Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1689-96.

15.
16.

Pomegranate ellagitannin-derived metabolites inhibit prostate cancer growth and localize to the mouse prostate gland.

Seeram NP, Aronson WJ, Zhang Y, Henning SM, Moro A, Lee RP, Sartippour M, Harris DM, Rettig M, Suchard MA, Pantuck AJ, Belldegrun A, Heber D.

J Agric Food Chem. 2007 Sep 19;55(19):7732-7. Epub 2007 Aug 28.

PMID:
17722872
17.

The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.

Wilt TJ, Brawer MK, Barry MJ, Jones KM, Kwon Y, Gingrich JR, Aronson WJ, Nsouli I, Iyer P, Cartagena R, Snider G, Roehrborn C, Fox S.

Contemp Clin Trials. 2009 Jan;30(1):81-7. doi: 10.1016/j.cct.2008.08.002. Epub 2008 Aug 23.

PMID:
18783735
18.

Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level.

Leibovici D, Spiess PE, Agarwal PK, Tu SM, Pettaway CA, Hitzhusen K, Millikan RE, Pisters LL.

Cancer. 2007 Jan 15;109(2):198-204.

19.

Herbal therapy PC-SPES: in vitro effects and evaluation of its efficacy in 69 patients with prostate cancer.

de la Taille A, Buttyan R, Hayek O, Bagiella E, Shabsigh A, Burchardt M, Burchardt T, Chopin DK, Katz AE.

J Urol. 2000 Oct;164(4):1229-34.

PMID:
10992371
20.

Effect of 13-cis-retinoic acid on serum prostate-specific antigen levels in patients with recurrent prostate cancer after radical prostatectomy.

Shalev M, Thompson TC, Frolov A, Lippman SM, Hong WK, Fritsche H, Kadmon D.

Clin Cancer Res. 2000 Oct;6(10):3845-9.

Supplemental Content

Support Center